INNOVADERM CRO IS NOW INDERO.

Strengthening data integrity in trials with subjective endpoints

Janet Overvelde

Janet Overvelde

Senior Director, Project Management

Author picture

Clinical trials that rely on subjective or semi-subjective endpoints, such as clinician-reported outcomes or patient-reported symptoms, face distinct challenges when it comes to data integrity.

This PharmaTimes Magazine article, written by Janet Overvelde, Indero’s Senior Director, Project Management, highlights some lessons learned in the dermatology field, which relies heavily on subjective outcomes, and outlines strategies for improving data integrity.

Read More

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

Fields marked with * are required.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.